Company intelligence / Profile preview

Shiyao

Shijiazhuang, Hebei, Chinashiyaoxia.com ↗

Ownership: Private
Employees: ~27000
Development stage: Other

Overview

Shiyao has over 90 independently innovated products under clinical development and about 400 clinical trials conducted domestically and internationally. Several innovative drugs have been approved for market launch in recent years. For example, the highly selective SOS1 inhibitor SYH2038 for advanced solid tumors was recently cleared for clinical testing in China; preclinical data show high selectivity and promising safety/efficacy profiles.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateBiologic
Industry: Pharma

Partnerships

Radiance Biopharma – exclusive out-license agreement for SYS6005 ADC in US/EU/Australia/Canada etc.

Beyond the preview

Go deeper on Shiyao.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shiyao.

Explore the full profile